Semaglutide

What it is

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and first approved by the FDA in 2017 for type 2 diabetes management. It's available in three formulations: Ozempic (subcutaneous injection for diabetes), Wegovy (higher-dose subcutaneous injection for weight management), and Rybelsus (oral tablet for diabetes).

This synthetic analog of human GLP-1 hormone has been modified with an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, allowing for convenient once-weekly dosing. The medication gained widespread attention for its remarkable weight loss effects, which led to its approval for chronic weight management in adults with obesity.

Semaglutide represents a breakthrough in metabolic medicine by effectively addressing both diabetes and obesity through a single mechanism. Its success sparked enormous demand and helped establish GLP-1 receptor agonists as the new standard of care for metabolic disorders, paving the way for next-generation compounds like tirzepatide and future triple-hormone agonists.

How it works

Semaglutide mimics the action of natural GLP-1, an incretin hormone released by intestinal L-cells in response to food intake. When semaglutide binds to GLP-1 receptors on pancreatic beta cells, it stimulates glucose-dependent insulin secretion, meaning insulin is only released when blood glucose levels are elevated.

Simultaneously, semaglutide suppresses glucagon secretion from pancreatic alpha cells, preventing the liver from producing excess glucose when it's not needed. This dual action on insulin and glucagon helps maintain normal blood sugar levels without causing dangerous hypoglycemia (low blood sugar) episodes.

The medication's weight loss effects occur through multiple pathways. Semaglutide activates GLP-1 receptors in the hypothalamus, the brain region controlling appetite and satiety, leading to significant reduction in food intake and cravings. It also slows gastric emptying, meaning food stays in the stomach longer, promoting feelings of fullness and reducing meal size.

Additional metabolic benefits include improved insulin sensitivity, preservation of pancreatic beta cell function, and potential cardiovascular protective effects through mechanisms including improved endothelial function and reduced inflammation. The medication's effects begin within hours but reach maximum effectiveness after 8-12 weeks of steady dosing.

What the research shows

The STEP (Semaglutide Treatment Effect in People with obesity) trial program provides the most comprehensive weight loss data for semaglutide. In STEP-1, the largest trial involving 1,961 adults with obesity, participants using semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks compared to 2.4% with placebo (Wilding et al., New England Journal of Medicine, 2021. PMID: 33567185).

Remarkably, 32% of participants achieved at least 20% weight loss, and 69% achieved at least 10% weight loss with semaglutide, compared to 2% and 12% respectively with placebo. These results represented the most effective obesity medication outcomes achieved in clinical trials at the time of publication.

For diabetes management, the SUSTAIN trial program demonstrated superior glycemic control compared to other diabetes medications. SUSTAIN-6, a cardiovascular outcomes trial involving 3,297 patients, showed that semaglutide significantly reduced major adverse cardiovascular events by 26% compared to placebo, including reduced rates of heart attack and stroke (Marso et al., New England Journal of Medicine, 2016. PMID: 27633186).

The SELECT trial, published in 2023, examined semaglutide's cardiovascular benefits in people with obesity but without diabetes. Among 17,604 participants followed for over 3 years, semaglutide 2.4 mg weekly reduced major cardiovascular events by 20%, demonstrating that the cardiovascular benefits extend beyond diabetes management to obesity treatment (Lincoff et al., New England Journal of Medicine, 2023. PMID: 37952131).

Typical protocol

Semaglutide injection protocols follow a standardized dose escalation schedule to minimize gastrointestinal side effects. For weight management (Wegovy), treatment starts with 0.25 mg subcutaneously once weekly for 4 weeks, then increases to 0.5 mg weekly for 4 weeks, followed by 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, and finally 2.4 mg weekly as the maintenance dose.

For diabetes management (Ozempic), the typical starting dose is 0.25 mg weekly for 4 weeks, then 0.5 mg weekly. The dose can be increased to 1 mg weekly and up to 2 mg weekly based on glycemic response and tolerability. Most patients achieve good results at 1-2 mg weekly for diabetes control.

Compounded semaglutide is typically reconstituted with bacteriostatic water to concentrations of 1-2 mg per mL. Store refrigerated and use within 28 days of reconstitution. Inject subcutaneously in the abdomen, thigh, or upper arm, rotating injection sites to prevent lipodystrophy. Calculate exact volumes using our peptide calculator.

Timing is flexible but should be consistent week to week. The injection can be administered any time of day, with or without meals. If a dose is missed, administer within 5 days of the scheduled dose; otherwise skip and resume regular schedule. For oral semaglutide (Rybelsus), take 30 minutes before first meal with minimal water and avoid eating for 30 minutes after dosing to optimize absorption.

Side effects and risks

Gastrointestinal side effects are the most common adverse events with semaglutide, occurring in 70-80% of users. Nausea affects approximately 75% of patients, particularly during dose escalation, and typically decreases after 4-8 weeks of consistent dosing. Vomiting, diarrhea, constipation, and abdominal pain are also frequent, especially when doses are increased too rapidly.

These gastrointestinal effects are dose-dependent and can be managed through slower titration schedules, dietary modifications, and temporary dose reductions. However, severe symptoms lead to treatment discontinuation in approximately 15-20% of patients in clinical trials.

Serious risks include potential acute pancreatitis, occurring in 0.2-0.3% of patients. Symptoms include severe abdominal pain that may radiate to the back, nausea, and vomiting. Treatment must be discontinued immediately if pancreatitis is suspected. Gallbladder problems, including gallstones and inflammation, may occur due to rapid weight loss and altered gallbladder motility.

Semaglutide carries a black box warning regarding potential thyroid C-cell tumors, based on animal studies showing increased incidence of medullary thyroid carcinomas in rodents. While no human cases have been definitively linked to semaglutide, it's contraindicated in patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. The medication should be avoided during pregnancy and breastfeeding, and may delay absorption of oral medications due to slowed gastric emptying.

Related compounds